Patients nix genetic tests due to cost, says study

| | June 12, 2012
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Pennsylvania researchers have discovered that a sizable percentage of patients potentially at risk for cancer would turn down testing to uncover genes linked to the disease. While their study named cost as the most likely reason, a number of other factors could influence individuals to nix the tests.

View the original article here: Patients Nix Genetic Tests Due to Cost: Study

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend